Critical Review: NeuroOne Medical Technologies (NASDAQ:NMTC) and PolyPid (NASDAQ:PYPD)
Critical Review: NeuroOne Medical Technologies (NASDAQ:NMTC) and PolyPid (NASDAQ:PYPD)
NeuroOne Medical Technologies (NASDAQ:NMTC – Get Rating) and PolyPid (NASDAQ:PYPD – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk.
納斯達克：NMTC-GET Rating和納斯達克：PYPD-GET Rating都是小盤醫療公司，但哪一家的業務更好？我們將根據這兩家公司的收益、分析師建議、股息、機構所有權、估值、盈利能力和風險等方面的實力進行比較。
Profitability
盈利能力
This table compares NeuroOne Medical Technologies and PolyPid's net margins, return on equity and return on assets.
此表比較了NeuroOne醫療技術公司和PolyPid的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| NeuroOne Medical Technologies | -7,177.71% | -97.47% | -88.76% |
| PolyPid | N/A | -193.77% | -128.47% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| NeuroOne醫療技術 | -7,177.71% | -97.47% | -88.76% |
| PolyPid | 不適用 | -193.77% | -128.47% |
Institutional & Insider Ownership
機構與內部人持股
2.6% of NeuroOne Medical Technologies shares are owned by institutional investors. 7.6% of NeuroOne Medical Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
NeuroOne Medical Technologies 2.6%的股份由機構投資者持有。NeuroOne Medical Technologies 7.6%的股份由內部人士持有。強大的機構持股表明，對衝基金、大型基金管理公司和捐贈基金相信，一隻股票有望實現長期增長。
Volatility & Risk
波動性與風險
Valuation and Earnings
估值和收益
This table compares NeuroOne Medical Technologies and PolyPid's revenue, earnings per share (EPS) and valuation.
此表比較了NeuroOne醫療技術公司和PolyPid的收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NeuroOne Medical Technologies | $180,000.00 | 139.58 | -$9.95 million | ($0.76) | -2.04 |
| PolyPid | N/A | N/A | -$42.60 million | ($2.43) | -0.31 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| NeuroOne醫療技術 | $180,000.00 | 139.58 | -995萬美元 | ($0.76) | -2.04 |
| PolyPid | 不適用 | 不適用 | -4,260萬美元 | ($2.43) | -0.31 |
NeuroOne Medical Technologies has higher revenue and earnings than PolyPid. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.
NeuroOne醫療技術公司的收入和收益比PolyPid更高。NeuroOne Medical Technologies的市盈率低於PolyPid，這表明它目前是兩隻股票中更負擔得起的一隻。
Analyst Ratings
分析師評級
This is a summary of recent recommendations and price targets for NeuroOne Medical Technologies and PolyPid, as provided by MarketBeat.
這是由MarketBeat提供的對NeuroOne醫療技術公司和PolyPid的最近建議和目標價格的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NeuroOne Medical Technologies | 0 | 1 | 1 | 0 | 2.50 |
| PolyPid | 0 | 1 | 3 | 0 | 2.75 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| NeuroOne醫療技術 | 0 | 1 | 1 | 0 | 2.50 |
| PolyPid | 0 | 1 | 3 | 0 | 2.75 |
NeuroOne Medical Technologies presently has a consensus price target of $2.63, indicating a potential upside of 69.35%. PolyPid has a consensus price target of $11.63, indicating a potential upside of 1,444.23%. Given PolyPid's stronger consensus rating and higher possible upside, analysts plainly believe PolyPid is more favorable than NeuroOne Medical Technologies.
NeuroOne Medical Technologies目前的共識目標價為2.63美元，表明潛在漲幅為69.35%。PolyPid的普遍目標價為11.63美元，表明潛在上行空間為1,444.23%。考慮到PolyPid更高的共識評級和更高的可能上行空間，分析師顯然認為PolyPid比NeuroOne醫療技術公司更有利。
Summary
摘要
NeuroOne Medical Technologies beats PolyPid on 7 of the 13 factors compared between the two stocks.
NeuroOne Medical Technologies在兩隻股票之間進行比較的13個因素中，有7個超過了PolyPid。
About NeuroOne Medical Technologies
關於NeuroOne醫療技術公司
(Get Rating)
(獲取評級)
NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.
NeuroOne醫療技術公司是一家醫療技術公司。該公司專注於薄膜電極技術的開發和商業化，用於連續腦電(CEEG)和立體腦電(SEEG)記錄、脊髓刺激、腦刺激和用於癲癇、帕金森病、肌張力障礙、特發性震顫、背部手術失敗導致的慢性疼痛和其他相關神經疾病患者的消融解決方案。它與RBC醫療創新公司建立了戰略合作伙伴關係，開發了一種射頻消融發生器，與NeuroOne的組合記錄和消融電極一起使用，以記錄大腦活動並使用相同的電極消融腦組織。該公司總部設在明尼蘇達州的伊甸園草原。
About PolyPid
關於PolyPid
(Get Rating)
(獲取評級)
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
PolyPid有限公司是一家處於後期階段的生物製藥公司，開發、製造和銷售基於聚合物-脂質膠囊基質(PLEX)平臺的產品，以滿足未得到滿足的醫療需求。它的主要候選產品是D-PLEX100，這是一種用於預防胸骨(骨)手術部位感染(SSI)以及預防腹部(軟組織)SSI的第三階段臨牀試驗。PolyPid有限公司成立於2008年，總部設在以色列佩塔提克瓦。
Receive News & Ratings for NeuroOne Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroOne Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
接受NeuroOne醫療技術日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對NeuroOne Medical Technologies和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。